These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 8905249)

  • 21. Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil in achieving 24-hour blood pressure reductions and ambulatory blood pressure goals.
    Brunner HR; Arakawa K
    Clin Drug Investig; 2006; 26(4):185-93. PubMed ID: 17163250
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clevidipine: a review of its use in the management of acute hypertension.
    Deeks ED; Keating GM; Keam SJ
    Am J Cardiovasc Drugs; 2009; 9(2):117-34. PubMed ID: 19331440
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Trough: peak ratio: the rationale behind the United States Food and Drug Administration recommendations.
    Lipicky RJ
    J Hypertens Suppl; 1994 Nov; 12(8):S17-8; discussion S18-9. PubMed ID: 7707150
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Amlodipine; clinical relevance of a unique pharmacokinetic profile.
    Meredith PA; Elliott HL
    J Cardiovasc Pharmacol; 1993; 22 Suppl A():S6-8. PubMed ID: 7522286
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Etamicastat, a novel dopamine β-hydroxylase inhibitor: tolerability, pharmacokinetics, and pharmacodynamics in patients with hypertension.
    Almeida L; Nunes T; Costa R; Rocha JF; Vaz-da-Silva M; Soares-da-Silva P
    Clin Ther; 2013 Dec; 35(12):1983-96. PubMed ID: 24296323
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical implications of indapamide sustained release 1.5 mg in hypertension.
    Donnelly R
    Clin Pharmacokinet; 1999; 37 Suppl 1():21-32. PubMed ID: 10491730
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics and pharmacodynamics of amlodipine.
    Abernethy DR
    Cardiology; 1992; 80 Suppl 1():31-6. PubMed ID: 1534713
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ambulatory blood pressure monitoring in the diagnosis of hypertension and evaluation of antihypertensive drug efficacy.
    Mancia G; Omboni S; Parati G; Ravogli A; Sega R; Ulian L
    Blood Press Suppl; 1994; 2():20-2. PubMed ID: 8061841
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analysis of trough:peak ratio and the assessment of anti-hypertensive drug action.
    Elliott HL; Meredith PA
    J Hum Hypertens; 1995 Jun; 9(6):423-7. PubMed ID: 7473522
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of trough:peak ratio in the assessment of antihypertensive drug therapy.
    Myers MG
    Can J Cardiol; 1994 Nov; 10 Suppl D():17D-20D. PubMed ID: 7954034
    [TBL] [Abstract][Full Text] [Related]  

  • 31. How to evaluate the duration of blood pressure control: the trough:peak ratio and 24-hour monitoring.
    Meredith PA
    J Cardiovasc Pharmacol; 1998; 31 Suppl 2():S17-21. PubMed ID: 9605597
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [24-hour blood pressure determination: therapeutic and prognostic implications].
    Vetter W; Schmid-Zumstein A; Bättig B; Oertel R; Hany S; Edmonds D; Baumgart P; Vetter H
    Schweiz Rundsch Med Prax; 1987 Apr; 76(17):462-6. PubMed ID: 3602764
    [No Abstract]   [Full Text] [Related]  

  • 33. Implications of the links between hypertension and myocardial infarction for choice of drug therapy in patients with hypertension.
    Meredith PA
    Am Heart J; 1996 Jul; 132(1 Pt 2 Su):222-8. PubMed ID: 8677860
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of fixed-dose combinations of telmisartan/hydrochlorothiazide 40/12.5 mg and 80/12.5 mg and a fixed-dose combination of losartan/hydrochlorothiazide 50/12.5 mg in mild to moderate essential hypertension: pooled analysis of two multicenter, prospective, randomized, open-label, blinded-end point (PROBE) trials.
    Lacourcière Y; Neutel JM; Schumacher H
    Clin Ther; 2005 Nov; 27(11):1795-805. PubMed ID: 16368450
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Shortcomings in the trough to peak ratio as a guide to the dose interval for antihypertensive drugs.
    Millar JA
    J Hum Hypertens; 1998 Jan; 12(1):37-44. PubMed ID: 9482132
    [No Abstract]   [Full Text] [Related]  

  • 36. Methodology to determine duration of action for antihypertensive drugs.
    Lefebvre J; Poirier L; Lacourcière Y
    Ann Pharmacother; 2002 May; 36(5):874-81. PubMed ID: 11978167
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Investigations of the antihypertensive long-term action of candesartan cilexetil in different dosages under the influence of therapy-free intervals].
    Weisser B; Gerwe M; Braun M; Funken C
    Arzneimittelforschung; 2005; 55(9):505-13. PubMed ID: 16229114
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intrinsically long-acting agents compared with long-acting chronoformulations.
    Meredith PA
    Blood Press Monit; 2000; 5 Suppl 1():S25-30. PubMed ID: 10904239
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relation of blood pressure response to therapy and the occurrence of myocardial infarction and stroke.
    Alderman MH; Madhavan S; Stanback ME; Davis TK
    J Cardiovasc Pharmacol; 1982; 4 Suppl 2():S251-6. PubMed ID: 6177968
    [No Abstract]   [Full Text] [Related]  

  • 40. The implications of noncompliance with antihypertensive medication.
    Girvin B; Johnston GD
    Drugs; 1996 Aug; 52(2):186-95. PubMed ID: 8841737
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.